No Data
No Data
HK stock market anomaly | Most pharmaceutical stocks are strong, with a number of bullish policies coming out successively this year, which is expected to promote the long-term increase in trading volume of innovative drugs in the country.
Most pharmaceutical stocks are performing well, as of the time of publication, Lai Kai zai lab-B (02105) rose by 12.27%, closing at 8.05 Hong Kong dollars; zai lab (09688) rose by 11.72%, closing at 22.4 Hong Kong dollars; Ho Yu-B (02256) rose by 9.6%, closing at 3.88 Hong Kong dollars.
HK Stocks | Innocare (09969) now rises more than 5%, positive results from ICP-488 Phase II trial, institutions bullish on TYK2 silver psoriasis treatment market
Innocare (09969) is now up more than 5%, as of the time of publication, up 5.28%, at 6.78 Hong Kong dollars, with a turnover of 14.0189 million Hong Kong dollars.
gtja: Bullish on innovative drugs policy, expected to continue to advance. Chinese patent medicine centralized procurement may face accelerated expansion.
With the support of the entire chain, innovative drugs have seen a series of bullish policies introduced in various regions, and favorable policies are expected to continue to advance in the future; centralized procurement of chinese patent medicine may accelerate its expansion.
UBS Group: Maintains a "buy" rating on Innocare (09969) with a target price raised to 8.6 Hong Kong dollars.
UBS Group believes that the research results of the second phase can support the third phase of the study.
InnoCare Pharma's Phase 2 Study of Plaque Psoriasis Drug Results Show Positive Results
InnoCare Announces Breakthrough Psoriasis Drug Results
No Data
No Data